By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC

Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.

Extension of the proverbial tail of the survival curve has provided disease relief, time, hope and, in some instances, remarkable, functional cures in an unparalleled number of tumor indications. But, as much as I-O has changed cancer care forever, things stay the same. Cancer still afflicts far too many people we know and biopharmaceutical research and development still struggles to find effective treatment options for ever evolving patients in need.

The promise of I-O was followed by the painful reminder that the next generation of I-O was not going to be a ‘gimme’ – no freebies as coaches liked to say. Despite lots of fanfare, the large number of new I-O targets and innumerable approaches to and combinations of those targets has mostly resulted in disappointment, with little to show for it other than proving the remarkable brilliance of anti-PD(L)1. Challenges abound in the lack of reliable preclinical models (reviewed in Ochoa de Olza and Garralda 2018 Annals of Oncology; Hegde and Chen 2020 Immunity), the systematic failures in clinical / translational experimental designs (retrospective summary by C. Pan et al J Hematol Onc 2020: 13, 29) and even some ill advised investments and scientific decision making.

There are too many examples to name but rather than dwell on the negatives, we need to reflect on the learnings, refocus on the positive takeaways and get back to work – cancer patients expect it. If one steps back and thinks about I-O in the context of an innovation cycle (see Figure 1 below), the remarkable success of anti-PD1 was really the result of tough learnings from predecessor approaches, even those that ‘worked’ like IL-2 and anti-CTLA4.

Figure 1 Innovation cycle for immuno-oncology field

The so-called ‘failure’ of many subsequent mechanisms over the past several years actually provided a roadmap on how to course-correct our thinking and approaches, and recent data has given us hope once again that I-O is here to stay.

Specifically, a number of important mechanisms are showing promise (see Figure 2 below):

Figure 2 New I-O mechanisms demonstrating validation in patients

What’s different now you might ask? The tough learnings from just a few years ago reminded us to

Our take is that these recent successes are part of the natural evolution of I-O innovation. There can and should be great optimism but with a splash of realism. There is huge therapeutic promise in re-directing the immune system to detect and destroy cancer cells in even more patient segments and while many approaches may still not work, there is so much value, scientifically, clinically and financially, in trying.

Despite the enormous benefits of I-O, the majority of patients don’t respond or don’t respond long enough – and yet we know the body’s immune system is a powerful therapeutic tool. We need to be more focused than ever to target the most legitimate approaches and ask the right questions in the right ways. We need to: